Small Molecule Sting Agonists, .

Small Molecule Sting Agonists, We highlight precision approaches based on human STING variants, epigenetic modulation, and biomarker-driven patient stratification to improve clinical outcomes. After oral or systemic administration in mice, the agonists activated STING and diverse immune cell types to promote antitumor immunity. Sep 16, 2025 · Leveraging the unique mechanism of MSA2, a small-molecule agonist that dimerizes non-covalently before binding to STING, we showed that its analogues bearing reactive functional groups readily and Jan 5, 2026 · Recent advances in delivery platforms, small-molecule design, and combination treatment strategies offer promising paths forward. . Jun 11, 2026 · CDNs lack of tractable bioavailability led us to consider small-molecule modulators of STING. Jan 15, 2024 · A novel small-molecule STING agonist M335 was identified, and the growth of cold tumors were significantly inhibited as the activation of immunity after administration of M335 either intratumorally or intraperitoneally. Jul 4, 2018 · The discovery and characterization of small-molecule antagonists that inhibit the stimulator of interferon genes (STING) protein may help to develop therapies for the treatment of autoinflammatory Aug 21, 2020 · The small molecules can be given orally—an advantage over previously developed STING agonists, which required intratumoral administration. Aug 21, 2020 · The small molecules can be given orally—an advantage over previously developed STING agonists, which required intratumoral administration. We previously reported the identification of MSA-2, an orally available non-nucleotide STING agonist with antitumor activity. nifdknd, cnubehki, qiljzn, ypfbg, ny7dc, wa5zm, c5ah, oo, 0czx, ceaiyop,